Loading…
Genetic diversity and antimicrobial susceptibility of Nocardia species among patients with nocardiosis
The aim of this multicenter study was to determine the genetic diversity and antibiotic susceptibility of clinically isolated Nocardia species. One hundred twenty-seven patients with nocardiosis were randomly selected from 5 provinces of Iran. Molecular diagnosis of Nocardia species was performed us...
Saved in:
Published in: | Scientific reports 2015-12, Vol.5 (1), p.17862-17862, Article 17862 |
---|---|
Main Authors: | , , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Summary: | The aim of this multicenter study was to determine the genetic diversity and antibiotic susceptibility of clinically isolated
Nocardia
species. One hundred twenty-seven patients with nocardiosis were randomly selected from 5 provinces of Iran. Molecular diagnosis of
Nocardia
species was performed using multilocus sequence analysis of gyrase B of the β subunit of DNA topoisomerase (
gyrB
) and 16S rRNA and subunit A of SecA preproteintranslocase (
secA1
). Antimicrobial susceptibility testing was performed following the Clinical and Laboratory Standards Institute recommendations. Thirty-five
N. cyriacigeorgica
, 30
N. asteroides
, 26
N. farcinica
, 12
N. otitidiscaviarum,
and 10
N. abscessus
cultures were studied. All isolates were susceptible to linezolid. All isolates of
N. cyriacigeorgica
,
N. asteroides, N. abscessus and N. otitidiscaviarum
were susceptible to trimethoprim-sulfamethoxazole, while 8% of
N. farcinica
isolates were resistant to this drug. All
N. otitidiscaviarum
isolates were highly resistant to imipenem, but
N. cyriacigeorgica
,
N. asteroides, N. farcinica and N. abscessus
were only moderate resistant. The susceptibility patterns vary with different species of
Nocardia
. Resistance to trimethoprim-sulfamethoxazole in Iran is low and this drug should be first line therapy, unless drug susceptibility testing shows resistance. Linezolid also covers
Nocardia
well and could be a second line agent. |
---|---|
ISSN: | 2045-2322 2045-2322 |
DOI: | 10.1038/srep17862 |